Table 2.
Comparison results of periodontal clinical parameters
| parameters | Group 1 | Group 1 (within-group p value)# | Group 2 | Group 2 (within-group p value) | p value between groups* | |
|---|---|---|---|---|---|---|
| PI (med (min-max)) | T0 | 1.17 (0.98–1.75) | 0.004 (T 0 -T 1 ) | 1.25 (1-4.3) | 0.001 (T 0 -T 1 ) | 0.273 |
| T1 | 1.05 (0.33–1.22) | 1.00 (T1-T2) | 1.08 (0.16–1.5) | 0.741 (T1-T2) | 0.361 | |
| T2 | 0.98 (0.2–1.45) | < 0.001 (T 0 -T 2 ) | 1.1 (0.5–1.5) | 0.033 (T 0 -T 2 ) | 0.006 | |
| GI (med (min-max)) | T0 | 1.26 (0.87–1.68) | 0.001 (T 0 -T 1 ) | 1.34 (0.87–3.1) | 0.010 (T 0 -T 1 ) | 0.378 |
| T1 | 1.1 (0.55–1.42) | 1.00 (T1-T2) | 1.16 (0.27–1.62) | 1.00 (T1-T2) | 0.423 | |
| T2 | 1.02(0.33–1.35) | < 0.001 (T 0 -T 2 ) | 1.12 (0.33–1.48) | < 0.001 (T 0 -T 2 ) | 0.078 | |
| BOP (%; med (min-max)) | T0 | 31.5 (13.33-82) | < 0.001 (T 0 -T 1 ) | 36.84 (17.8–85) | 0.003 (T 0 -T 1 ) | 0.358 |
| T1 | 15(3.7–47) | 1.00 (T1-T2) | 22.22 (7.4–60) | 1.00 (T1-T2) | 0.020 | |
| T2 | 15 (4.54–41.2) | < 0.001 (T 0 -T 2 ) | 21.5 (3.84-46) | < 0.001 (T 0 -T 2 ) | 0.217 | |
| PPD (mm; mean ± SD) | T0 | 2.61 ± 0.33 | < 0.001 (T 0 -T 1 ) | 2.54 ± 0.52 | 0.080 (T0-T1) | 0.593 |
| T1 | 2.32 ± 0.34 | 1.00 (T1-T2) | 2.37 ± 0.36 | 1.00 (T1-T2) | 0.637 | |
| T2 | 2.36 ± 0.37 | 0.018 (T 0 -T 2 ) | 2.37 ± 0.32 | 0.191 (T0-T2) | 0.912 | |
| CAL (mm; mean ± SD) | T0 | 2.8 ± 0.31 | 0.005 (T 0 -T 1 ) | 2.8 ± 0.49 | 0.029 (T 0 -T 1 ) | 0.997 |
| T1 | 2.55 ± 0.35 | 1.00 (T1-T2) | 2.6 ± 0.41 | 1.00 (T1-T2) | 0.676 | |
| T2 | 2.54 ± 0.4 | 0.007 (T 0 -T 2 ) | 2.57 ± 0.35 | 0.019 (T 0 -T 2 ) | 0.797 |
Numbers in bold indicate a statistically significant difference
PI plaque index, GI gingival index, BOP bleeding on probing, PPD probing pocket depth, CAL clinical attachment loss. T0; baseline. T1; 3 months after non-surgical periodontal treatment (NSPT). T2; 6 months after NSPT. med; median. min; minimum. max; maximum. SD; standard deviation. RA; rheumatoid arthritis. Group 1; individuals with RA and periodontitis who were not receiving anti-TNF-α therapy. Group 2; individuals with RA and periodontitis under anti-TNF-α treatment for a minimum duration of one year. *: Independent Sample t Test or Mann Whitney-U Test. #: Generalized Linear Repeated Measures or Friedman test